Effect of glucagon‐like peptide‐1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta‐analysis of placebo‐controlled randomized trials-Reference-Cited by-同舟云学术

Effect of glucagon‐like peptide‐1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta‐analysis of placebo‐controlled randomized trials

Published:2022-05-03 Issue:8 Volume:24 Page:1676-1680
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Leite Ana Rita¹²^ORCID,Angélico‐Gonçalves António¹²^ORCID,Vasques‐Nóvoa Francisco¹²³^ORCID,Borges‐Canha Marta¹²⁴^ORCID,Leite‐Moreira Adelino¹²^ORCID,Neves João Sérgio¹²⁴^ORCID,Ferreira João Pedro¹²⁵^ORCID

Affiliation:

1. Cardiovascular R&D Center, Faculty of Medicine University of Porto Porto Portugal

2. Department of Surgery and Physiology, Faculty of Medicine University of Porto Porto Portugal

3. Department of Internal Medicine Centro Hospitalar Universitário de São João, E.P.E Porto Portugal

4. Department of Endocrinology, Diabetes and Metabolism Centro Hospitalar Universitário de São João, E.P.E Porto Portugal

5. Centre d'Investigation Clinique‐Plurithématique INSERM CIC‐P 1433, INSERM U1116, CHRU Nancy Brabois, F‐CRIN INI‐CRCT, Université de Lorraine Nancy France

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14707

Reference14 articles.

1. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

2. RoB 2: a revised tool for assessing risk of bias in randomised trials

3. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of glucagon-like peptide-1 receptor agonists on cardiovascular events in overweight or obese non-diabetic patients;Current Problems in Cardiology;2024-03

2. Glucagon-Like Peptide-1 Receptor Agonists Across the Spectrum of Heart Failure;The Journal of Clinical Endocrinology & Metabolism;2023-07-06

3. Role of Glucagon‐Like Peptide‐1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity;Journal of the American Heart Association;2023-06-06

4. Absolute Benefits From Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors;Diabetes Care;2023-05-23

5. Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial;Diabetes, Obesity and Metabolism;2022-09-21